ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > poster analysis

<< Previous

Bullboard Posts

Next >>

Post by Gbathaton Oct 05, 2023 1:42pm

186 Views

Post# 35671478

poster analysis

https://d1io3yog0oux5.cloudfront.net/_723c1ce90d796a40ef5000eda2ca63ef/promisneurosciences/db/1004/8793/pdf/2023+AAIC+PMN310+poster.pdf

PMN's data in Figures 4 & 5 show head to head comparison w/ Acumen (ACU) and Prothena (PRX) products.

But go on Farmer, keep hyping the competition. Further ahead in timeline and funding does not equal better.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks